<DOC>
	<DOCNO>NCT00160420</DOCNO>
	<brief_summary>The objective study determine long-term safety asoprisnil 5 mg 12 month woman endometriosis study M01-398 .</brief_summary>
	<brief_title>A Long-Term Study Evaluate Safety Asoprisnil Treatment Women With Endometriosis From Study M01-398</brief_title>
	<detailed_description>Endometriosis , presence endometrial tissue outside uterus , progressive , estrogen-dependent disease occur menstruate woman reproductive age . Although major endometriosis therapy effective treatment pain , single treatment superior others term efficacy . The major drawback current medical therapy severe side effect hot flush osteoporosis . The objective study determine long-term safety asoprisnil 5 mg daily 12 month woman endometriosis , initial 12 week study M01-398 . The safety base assessment endometrium , lipid profile , adverse event , change baseline laboratory value vital sign .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Completed 3 month dose Month 3 procedure study M01398 Otherwise good health Month 3 ( M01398 ) ultrasound reveals significant gynecologic disorder Any abnormal lab procedure result studydoctor considers important Anticipated need exclude hormonal therapy unapproved narcotic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Pelvic pain</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Dyspareunia</keyword>
	<keyword>Infertility</keyword>
	<keyword>asoprisnil</keyword>
</DOC>